Asia Pacific Antibody Drug Conjugates Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031
Asia Pacific Antibody Drug Conjugates Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others), Target (HER2, CD22, CD30, and Others), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies)
- Report Date : Nov 2025
- Report Code : TIPRE00041552
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 217
The Asia Pacific Antibody Drug Conjugates Market size is expected to reach US$ 6,769.7 Million by 2031 from US$ 1,357.8 Million in 2023. The market is estimated to record a CAGR of 22.2% from 2023 to 2031.
Executive Summary and Asia Pacific Antibody Drug Conjugates Market Analysis:The Asia Pacific antibody drug conjugates market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The Asia-Pacific antibody-drug conjugates (ADC) market is primarily driven by the increase in cancer cases, alongside rising investments in ADC research and technology. Innovations in linker technologies and cytotoxic agents have improved the efficacy and safety of ADCs. Furthermore, favorable regulatory frameworks in countries like Japan have supported ADC development. The market is highly competitive, with major global players such as Pfizer, AstraZeneca, and Roche taking the lead. Emerging biotech firms like HaemaLogiX and BioNTech are also making significant advancements, increasing competition. Collaborations, including partnerships by Ono Pharmaceutical and growing support for local biotech innovation, further intensify rivalry in the market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Asia Pacific Antibody Drug Conjugates Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- By Technology, the Asia Pacific Antibody Drug Conjugates Market is segmented into Cleavable Linker and Non-cleavable Linker. Cleavable Linker held the largest share of the market in 2023.
- By Application, the Asia Pacific Antibody Drug Conjugates Market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. Breast Cancer held the largest share of the market in 2023.
- By Target, the Asia Pacific Antibody Drug Conjugates Market is segmented into HER2, CD22, CD30, and Others. HER2 held the largest share of the market in 2023.
- By Distribution Channel, the Asia Pacific Antibody Drug Conjugates Market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Hospital Pharmacies held the largest share of the market in 2023.
The expansion into new indications is creating significant opportunities in the antibody-drug conjugates market. As antibody-drug conjugates are primarily designed to deliver cytotoxic agents directly to cancer cells while sparing healthy tissues, their ability to target specific tumor-associated antigens makes them highly versatile. This versatility allows for exploring antibody-drug conjugate applications beyond their initial indications, i.e., hematological malignancies and certain solid tumors. Many cancers currently lack adequate treatment options, and introducing antibody-drug conjugates targeting new biomarkers can provide innovative therapies for these challenging conditions. For instance, antibody-drug conjugates are being investigated for treating cancers such as breast, lung, and bladder cancers, where traditional therapies may not yield satisfactory results.
Additionally, the collaboration between pharmaceutical companies and research institutions fosters innovation in antibody-drug conjugate development. These partnerships often focus on identifying novel targets and optimizing linker technologies to enhance the efficacy and safety profiles of conjugates. Moreover, with the discovery and validation of new targets, antibody-drug conjugates are being further investigated for their potential utilization in the treatment of a broader range of cancer types. In June 2024, ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the development of innovative biopharmaceutical therapeutics, entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly owned subsidiary of Alphamab Oncology, to discover, develop, and commercialize novel antibody-drug conjugates for the treatment of cancers. By addressing unmet medical needs, benefiting from favorable regulatory conditions, capitalizing on the rising prevalence of cancer, and fostering collaborative innovation, antibody-drug conjugates are poised to play a pivotal role in the future of targeted cancer therapies. Thus, an expansion into new indications presents a wealth of opportunities for the antibody-drug conjugates market.
Asia Pacific Antibody Drug Conjugates Market Country InsightsBy country, the Asia Pacific Antibody Drug Conjugates Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. Japan held the largest share in 2023.
Regulations for biopharmaceutical products in Japan vary significantly from those of the US FDA and the European Commission. In September 2021, Astellas Pharma Inc. and Seagen Inc. (acquired by Pfizer, Inc.) received approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan for its PADCEV (enfortumab vedotin) antibody-drug conjugate. The product is intended to treat relapsed, radically unresectable urothelial cancer after receiving anti-cancer chemotherapy. The approval is based on the positive outcomes of the global Phase 3 EV-301 clinical trial in Japan. Some Japanese companies are also introducing breakthrough products that are expected to dominate the antibody-drug conjugates market. In June 2021, Eisai Co., Ltd. and Bristol-Myers Squibb Company entered into an exclusive global collaboration agreement for the joint development and commercialization of MORAb-202, Eisai's first antibody-drug conjugate. MORAb-202 is being investigated in patients with folate receptor alpha (FRα)-positive solid tumors, including endometrial, ovarian, lung, and breast cancers, through a Phase 1 study in Japan. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, ImmunoGen's antibody-drug conjugate therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. received upfront and additional payments upon conversion of ELAHERE's accelerated approval by FDA in platinum-resistant ovarian cancer (PROC) to full approval. Under this arrangement, Takeda would pay an additional payment to ImmunoGen, Inc. upon achieving certain regulatory and commercial milestones, and double-digit royalties through the net sales of ELAHERE in Japan. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. Takeda is also responsible for all regulatory filings and will have an exclusive license to develop and commercialize ELAHERE in Japan.
Asia Pacific Antibody Drug Conjugates Market Company ProfilesSome of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA.
These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Asia Pacific Antibody Drug Conjugates Market Research MethodologyThe following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites,
annual reports, financial statements, broker analyses, and investor presentationsIndustry trade journals
and other relevant publicationsGovernment documents,
statistical databases, and market reportsNews articles,
press releases, and webcasts specific to companies operating in the market
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.Primary Research
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research
- Enhance the expertise and market understanding of the analysis team
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
Industry stakeholders:
Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales ManagersExternal experts:
Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Antibody Drug Conjugates Market Landscape
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. Asia Pacific Antibody Drug Conjugates Market - Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. Antibody Drug Conjugates Market - Asia Pacific Market Analysis
6.1 Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 Asia Pacific Antibody Drug Conjugates Market Forecast and Analysis
7. Asia Pacific Antibody Drug Conjugates Market Revenue Analysis - by Technology
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. Asia Pacific Antibody Drug Conjugates Market Revenue Analysis - by Application
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. Asia Pacific Antibody Drug Conjugates Market Revenue Analysis - by Target
9.1 HER2
9.1.1 Overview
9.1.2 HER2: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. Asia Pacific Antibody Drug Conjugates Market Revenue Analysis - by Distribution Channel
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. Asia Pacific Antibody Drug Conjugates Market - Country Analysis
11.1 Asia Pacific
11.1.1 Asia Pacific Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Asia Pacific Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 China: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 China: Asia Pacific Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 China: Asia Pacific Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 China: Asia Pacific Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 China: Asia Pacific Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Japan: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Japan: Asia Pacific Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Japan: Asia Pacific Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Japan: Asia Pacific Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Japan: Asia Pacific Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 India: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 India: Asia Pacific Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 India: Asia Pacific Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 India: Asia Pacific Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 India: Asia Pacific Antibody Drug Conjugates Market Share - by Distribution Channel
11.4.5.5 Australia: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Australia: Asia Pacific Antibody Drug Conjugates Market Share - by Technology
11.4.5.5.2 Australia: Asia Pacific Antibody Drug Conjugates Market Share - by Application
11.4.5.5.3 Australia: Asia Pacific Antibody Drug Conjugates Market Share - by Target
11.4.5.5.4 Australia: Asia Pacific Antibody Drug Conjugates Market Share - by Distribution Channel
11.5.6.6 South Korea: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.5.6.6.1 South Korea: Asia Pacific Antibody Drug Conjugates Market Share - by Technology
11.5.6.6.2 South Korea: Asia Pacific Antibody Drug Conjugates Market Share - by Application
11.5.6.6.3 South Korea: Asia Pacific Antibody Drug Conjugates Market Share - by Target
11.5.6.6.4 South Korea: Asia Pacific Antibody Drug Conjugates Market Share - by Distribution Channel
11.6.7.7 Rest of APAC: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.6.7.7.1 Rest of APAC: Asia Pacific Antibody Drug Conjugates Market Share - by Technology
11.6.7.7.2 Rest of APAC: Asia Pacific Antibody Drug Conjugates Market Share - by Application
11.6.7.7.3 Rest of APAC: Asia Pacific Antibody Drug Conjugates Market Share - by Target
11.6.7.7.4 Rest of APAC: Asia Pacific Antibody Drug Conjugates Market Share - by Distribution Channel
12 Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 Industry Landscape
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. Asia Pacific Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. China: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. China: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. China: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. China: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Japan: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Japan: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Japan: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Japan: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. India: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. India: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. India: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. India: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Australia: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 22. Australia: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 23. Australia: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 24. Australia: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 25. South Korea: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 26. South Korea: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 27. South Korea: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 28. South Korea: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 29. Rest of APAC: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 30. Rest of APAC: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. Rest of APAC: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 32. Rest of APAC: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Heat Map Analysis by Key Players
List of Figures
Figure 1. Asia Pacific Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. Asia Pacific Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. Asia Pacific Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Asia Pacific Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Asia Pacific Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Asia Pacific Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. China: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Japan: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. India: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Australia: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. South Korea: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 32. Rest of APAC: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Company Positioning & Concentration
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For